ADMA Biologics ADMA US — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about ADMA Biologics's us — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ADMA Biologics's US — revenue?
- ADMA Biologics (ADMA) reported US — revenue of $113.43M in Q1 2026.
- How has ADMA Biologics's US — revenue changed year-over-year?
- ADMA Biologics's US — revenue increased by 2.4% year-over-year, from $110.73M to $113.43M.
- What is the long-term trend for ADMA Biologics's US — revenue?
- Over 4 years (2021 to 2025), ADMA Biologics's US — revenue has grown at a 63.4% compound annual growth rate (CAGR), from $70.63M to $504.07M.
- What does US — revenue mean?
- This metric represents the total gross revenue generated from the sale of plasma-derived biologics and related products within the United States market, net of any assessed taxes. It serves as a primary indicator of the company's commercial success and market penetration for its specialty therapeutic portfolio in the domestic region. Tracking this figure allows investors to evaluate the growth trajectory and demand for the company's core biopharmaceutical offerings.